ScholarLens Back to search
2020•Clinical Pulmonary MedicineRequires access

Clinical and Radiologic Improvement Following Tocilizumab Administration in Patients With SARS-CoV-2

Fotios Barkas, Angelos Liontos, Evgenia Svarna, Athina C. Tsili, Marianna Christaki, Iro Rapti, Maria I. Argyropoulou, Haralampos Milionis

Open publisher page 0 citations

Abstract

Cytokine release syndrome and acute respiratory distress syndrome are the major complications of coronavirus disease 2019 (COVID-19) and tocilizumab has shown efficacy in this setting. We report on 2 severely ill patients with COVID-19 treated with tocilizumab within 7 to 10 days of onset of symptoms. Tocilizumab markedly improved their clinical condition and was associated with regression of abnormalities on chest computed tomography within 1 week of tocilizumab administration.

About this research paper

What this paper is about

Cytokine release syndrome and acute respiratory distress syndrome are the major complications of coronavirus disease 2019 (COVID-19) and tocilizumab has shown efficacy in this setting. We report on 2 severely ill patients with COVID-19 treated with tocilizumab within 7 to 10 days of onset of symptoms. Tocilizumab markedly improved their clinical condition and was associated with regression of abnormalities on chest computed tomography within 1 week of tocilizumab administration.

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Cytokine release syndrome and acute respiratory distress syndrome are the major complications of coronavirus disease 2019 (COVID-19) and tocilizumab has shown efficacy in this setting. We report on 2 severely ill patients with COVID-19 treated with tocilizumab within 7 to 10 days of onset of symptoms. Tocilizumab markedly improved their clinical condition and was associated with regression of abnormalities on chest computed tomography within 1 week of tocilizumab administration.

Key concepts: Tocilizumab, Medicine, Cytokine release syndrome, Coronavirus disease 2019 (COVID-19), Acute respiratory distress, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Interleukin 6, Internal medicine

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
Clinical and Radiologic Improvement Following Tocilizumab Administration in Patients With SARS-CoV-2 — Research Paper | ScholarLens